Fulgent Genetics enters the back half of 2026 as a precision-medicine diagnostics company that is in the middle of a deliberate business-mix shift. Second-quarter revenue rose 4% year over year to $85.4 million, but the growth was not organic: it was purchased by the Bako Diagnostics and StrataDx acquisition closed in March, which contributed $12.9 million to anatomic pathology in the first half. Underneath that acquisition noise, the core laboratory franchise is under strain. Precision diagnostics revenue fell $6.0 million in the quarter as the company's largest customer, which had represented 22% of revenue a year earlier, continues to move testing in-house, and the final phase of a new billing and revenue cycle management system has produced processing backlogs and collections delays that compressed gross margin to 30% from 42%.
The strategic question is whether the Bako acquisition and the resolution of the revenue cycle transition can restore the margin structure that the equity was built on, while the declining largest-customer relationship is offset by new anatomic pathology and BioPharma services volume. The balance sheet is a genuine strength: $551.5 million in cash and marketable securities against a market capitalization near $540 million means the company has essentially no leverage and can self-fund both integration and its FID-007 clinical program. The forward catalyst is the Phase 2 readout of FID-007 in head and neck cancer, for which an end-of-Phase 2 meeting with the FDA is scheduled before the end of August 2026, with a Phase 3 start planned for the first half of 2027. The main risks are that the collections delays prove durable rather than transitional, that the largest-customer erosion outpaces new customer development, and that integration costs from Bako run above the level embedded in the current cost base.
The valuation setup here is atypical for a loss-making diagnostics company. At the recent close of $19.90, the market capitalization of roughly $547 million sits below the company's liquid net asset position, so the equity is effectively priced near the value of its cash while the operating laboratory business and the FID-007 program are almost free options on top. That framing makes the investment a test of execution rather than of entry price: the stock works if margin recovers toward the 40% level the company historically earned and if the Bako business scales, and it struggles if the revenue cycle issues persist and the customer base keeps concentrating in the wrong direction.